Correction revisits equine phenylbutazone IVRLP study

Frontiers in Veterinary Science has issued a correction to the paper, “Phenylbutazone concentrations in synovial fluid following administration via intravenous regional limb perfusion in the forelimbs of six adult horses,” with the correction published on July 1, 2026. The notice links back to the original 2023 article by investigators at Iowa State University, which explored whether PBZ could be delivered locally by IVRLP to support equine pain management while reducing the gastrointestinal, renal, and colitis risks associated with systemic NSAID exposure. (frontiersin.org)

That question matters because IVRLP is already well established in equine practice as a targeted delivery technique for distal limb infections, especially for antimicrobial administration. The appeal of adapting the method for analgesia is straightforward: if a familiar regional technique could achieve meaningful joint or soft-tissue NSAID concentrations without relying on repeated systemic dosing, it could offer another option for lameness and orthopedic pain cases. Reviews of regional limb perfusion literature have largely centered on infection management, underscoring how novel this PBZ study was when it first appeared. (frontiersin.org)

In the original experiment, six healthy adult horses each underwent bilateral forelimb procedures, with one forelimb randomly assigned to PBZ-IVRLP and the other to placebo. The PBZ perfusate used injectable 20% phenylbutazone at 2.2 mg/kg diluted to 60 mL, with a tourniquet maintained for 30 minutes. Investigators collected serum and radiocarpal synovial fluid samples from baseline through 24 hours, then monitored limbs clinically and by ultrasonography for seven days, followed by histopathology at the injection sites after euthanasia. (frontiersin.org)

The key finding was that the regional approach did not outperform systemic exposure. Mean synovial PBZ concentrations were 1.9 ± 2.1 μg/mL, significantly lower than mean serum concentrations of 5.8 ± 5.1 μg/mL. The active metabolite oxyphenbutazone also ran lower in synovial fluid than in serum. In the discussion, the authors said the results suggested PBZ remained in the peripheral vasculature more than it diffused into the radiocarpal joint, and they concluded that a single PBZ-IVRLP dose at 2.2 mg/kg was similar to a single systemic intravenous administration, with no additional clinical benefit demonstrated in these healthy standing horses. (frontiersin.org)

On safety, the picture was mixed but not alarming in this small dataset. Physical examinations and ultrasonographic measurements did not differ significantly between PBZ and placebo limbs, and no horse showed clinical signs of tissue myositis, necrosis, or observable lameness at the walk during the study period. Histologically, the most common findings were focal deep dermal or subcutaneous hemorrhage and edema. Two horses had perivasculitis, and one had a resolving cephalic vein thrombus in the PBZ limb, although that same horse also had severe inflammatory findings in the placebo limb. (frontiersin.org)

There does not appear to be a broad wave of outside commentary tied specifically to this newly posted correction, and the correction page itself says the final formatted version will be published soon. Still, the study has drawn attention because it tested a logical extension of a common equine technique. The broader IVRLP literature supports the method for achieving high local antimicrobial concentrations, but this paper suggests the same logic may not translate cleanly to phenylbutazone, at least not with the dose and protocol used here. That’s an inference based on the contrast between this paper’s findings and the established role of IVRLP in infection management. (frontiersin.org)

Why it matters: For veterinary professionals, especially equine clinicians, the correction is less about a practice-changing reversal and more about keeping the record straight around a study that already delivered a cautionary message. If pet parents ask about more “targeted” NSAID delivery for limb pain, this remains an example of why pharmacologic plausibility doesn’t always become clinical utility. The study was small, used healthy horses rather than clinical pain cases, and evaluated a single-dose protocol, but the available evidence still points away from PBZ-IVRLP as a meaningful alternative to standard systemic administration. (frontiersin.org)

What to watch: The next meaningful development would be the final formatted correction itself, followed by any new studies that test different perfusate volumes, longer tourniquet times, repeat dosing, or other analgesics better suited to local tissue diffusion. Until then, IVRLP’s strongest evidence base in horses remains on the antimicrobial side, not local NSAID delivery. (frontiersin.org)